Observational studyBrain and behavior2025
Practicability of Activating Transcription Factor 3 as a Serological Marker for Severity Appraisal and Outcome Anticipation in Acute Supratentorial Intracerebral Hemorrhage: A Two-center Observational Analytical Study.
Observational study in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundActivating transcription factor 3 (ATF3) is a neuroprotective factor and participates in acute brain injury. Here, we intend to determine whether serum ATF3 levels are associated with the severity and clinical outcomes of acute intracerebral hemorrhage (ICH).
methodsIn this two-center observational analytic study of 236 patients with supratentorial ICH and 114 controls, serum ATF3 levels were quantified at the admission of all patients, at study entry of all controls, and at serial time-points of 114 patients from all patients. The Admission National Institutes of Health Stroke Scale (NIHSS) and hematoma volume, and the modified Rankin Scale (mRS) at post-ICH six months were recorded. Outcome variables were stroke-associated pneumonia (SAP), early neurological deterioration (END), and post-ICH 6-month neurological status. Associations were appraised via multifactorial analyses.
resultsSerum ATF3 levels of patients consenting for serial sampling swiftly increased since admission, peaked until post-ICH day 3, then slowly declined up to day 14, and were significantly higher even on day 14 than those of controls. Dynamic serum ATF3 levels of patients consenting for serial sampling were firmly related to NIHSS scores, hematoma volume, SAP, END, continuous and ordinal mRS scores, and poor prognosis (mRS scores of 3-6). Even adjusting for possible confounding factors, associations of admission serum ATF3 levels with the preceding parameters still existed among all patients. Alternatively, admission serum ATF3 levels were linearly correlated with SAP, END, and poor prognosis under restricted cubic spline, and did not interact with age, sex, alcohol consumption and others via subgroup analysis. The associations were robust in sensitivity analysis. Through receiver operating characteristic (ROC) curve analysis, admission serum ATF3 levels had predictive ability comparable to that of NIHSS scores and hematoma volume.
conclusionElevated serum ATF3 levels following ICH are intimately correlated with disease severity and effectively predict END, SAP, and poor prognosis, solidifying serum ATF3 as a prognostic candidate of ICH.Elevated serum ATF3 levels following ICH are closely correlated with disease severity and effectively predict END, SAP, and poor prognosis, reinforcing serum ATF3 as a prognostic surrogate of ICH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.